Using Targeted Virotherapy to Treat a Resistant Ewing Sarcoma Model: From the Bedside to the Bench and Back
Figure 6
VSVΔM51 treatment leads to apoptosis of tumor cells and profound loss of tumor vasculature. At day 5 after treatment, subcutaneous tumors were harvested. IHC performed on tumor-frozen sections shows robust VSVΔM51 spread (a) within the tumor mass with corresponding tumor apoptosis (c). Microperfusion studies also indicated significant microvascular compromise postviral treatment (b). Normal controls are unaffected.
